Document 0037
 DOCN  M9580037
 TI    [Evaluation of serum adenosine deaminase as a prognostic marker in the
       treatment of human immunodeficiency virus infection with zidovudine]
 DT    9506
 AU    Carrera J; Porras JA; Vidal F; Pinto B; Richart C; Servicio de Analisis
       Clinicos, Hospital Universitari de; Tarragona Joan XXIII, Universidad
       Rovira i Virgili, Tarragona.
 SO    Rev Clin Esp. 1995 Feb;195(2):74-7. Unique Identifier : AIDSLINE
       MED/95249777
 AB    BACKGROUND. Adenosine deaminase (ADA) is a key enzyme in cellular
       immunity. It catalyses the reaction 2'deoxyadenosine to 2'deoxiinosine,
       a critical step in the production of essential metabolites for the
       synthesis of nucleic acids. Its main physiological activity occurs in T
       cells of lymphoid tissue. The advanced HIV infection is characterized by
       a severe and progressive cellular immunity compromise. Partial positive
       results have been obtained with Zidovudine (AZT), a drug which Serum
       adenosine deaminase has been proposed as a useful marker for the
       assessment of the therapy response in these patients. METHODS. Serum ADA
       activity was determined in patients infected with HIV in stage II,
       before and after four months of therapy with AZT, regarding variations
       in its activity with improvements in biological parameters--CD4 and CD8
       lymphocytes. RESULTS. Patients infected with HIV showed a significant
       increase in ADA activity compared with patients in the control group:
       21.6 +/- 5.4 vs. 10.4 +/- 2.3 U/l (p < 0.001). Therapy with AZT
       decreased ADA activity: 21.6 +/- 5.4 vs. 15.2 +/- 4.3 U/l (p < 0.001)
       and correlated with an increase in CD4 counts: 187 +/- 105 vs. 353 +/-
       145/mm3 (p < 0.001) and in CD4/CD8 ratio: 0.188 +/- 0.10 vs. 0.382 +/-
       0.18 (p < 0.001). CONCLUSIONS. The detection of a decrease in ADA
       correlates significantly with a favourable outcome in immunological
       parameters in individuals infected with HIV in stage II of disease
       treated with AZT.
 DE    Adenosine Deaminase/*BLOOD  Adolescence  Adult  Biological Markers/BLOOD
       Case-Control Studies  CD4-CD8 Ratio/DRUG EFFECTS  English Abstract
       Female  Human  HIV Infections/*BLOOD/*DRUG THERAPY/ENZYMOLOGY  Male
       Middle Age  Prognosis  Zidovudine/*THERAPEUTIC USE  JOURNAL ARTICLE

       SOURCE: National Library of Medicine.  NOTICE: This material may be
       protected by Copyright Law (Title 17, U.S.Code).